Hodnocení cytokinového imunobarvení u ovariálních novotvarů a endometriomů

Download PDF English version

Authors: Rosekeila Simões Nomelini ^1,2 ; Priscylla Kelliny Aparecida Antão ¹ ; Millena Prata Jammal ¹ ; Cid Almeida De Lima ¹ ; Paula Carolina Arvelos Crispim ¹ ; Agrimaldo Martins-Filho ¹ ; Renata Margarida Etchebehere ³ ; Eddie Fernando Candido Murta ¹
Authors‘ workplace: Laboratory of Applied Sciences for Women (LaCam)/ Department of Gynecology and Obstetrics, Federal University of Triângulo Mineiro, Uberaba-MG, Brazil ¹; Graduate Program in Gynecology and Obstetrics of the Ribeirão Preto Medical School of the University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil ²; Surgical Pathology Service, Federal University of Triângulo Mineiro, Uberaba-MG, Brazil ³
Published in: Ceska Gynekol 2024; 89(5): 377-384
Category: Original Article
doi: https://doi.org/10.48095/cccg2024377

Overview

Cíl: Cílem naší studie bylo kvantifikovat a porovnat imunobarvení IL-2, IL-5, IL-6, IL-8 a TNFa ve tkáni endometriomu, nenádorových nádorech, benigních novotvarech a maligních novotvarech vaječníků. Materiál a metody: Studie se zúčastnilo 90 pacientek; bylo dia gnostikováno 15 nenádorových lézí ovaria, 28 ovariálních benigních novotvarů, 28 ovariálních maligních novotvarů a 19 ovariálních endometriomů. Imunohistochemie byla provedena pro cytokiny IL-2, IL-5, IL-6, IL-8 a TNFa a jejich koncentrace byly v těchto skupinách porovnány. Použili jsme Fisherův exaktní test, podle něhož jsou významné hodnoty p < 0,05. Výsledky: Imunobarvení epitelu na přítomnost IL-5 a IL-8 je silnější u endometriomů než u karcinomu vaječníků (p hodnoty 0,0046 a 0,0149). Stromální imunobarvení TNFa, IL-5, IL-6 a IL8 je silnější u endometriomů než u rakoviny vaječníků (p hodnoty 0,0008; < 0,0001; 0,0003 a 0,0006). Závěr: Silnější imunobarvení ně kte rých cytokinů u endometriomů ve srovnání s karcinomem ovaria odráží zánětlivou a imunitní odpověď, která by mohla být budoucím cílem nových objevů o infiltrativním chování endometriózy.

Klíčová slova:

cytokiny – Endometrióza – imunologie – ovariální novotvary

Sources

1. Mao AJ, Anastasi JK. Dia gnosis and management of endometriosis: the role of the advanced practice nurse in primary care. J Am Acad Nurse Pract 2010; 22 (2): 109–116. doi: 10.1111/j.1745-7599.2009.00475.x.

2. Ruderman R, Pavone ME. Ovarian cancer in endometriosis: an update on the clinical and molecular aspects. Minerva Ginecol 2017; 69 (3): 286–294. doi: 10.23736/S0026-4784.17.04042-4.

3. Ahn SH, Monsanto SP, Miller C et al. Pathophysiology and immune dysfunction in endometriosis. Biomed Res Int 2015; 2015: 795976. doi: 10.1155/2015/795976.

4. Kok VC, Tsai HJ, Su CF et al. The risks for ovarian, endometrial, breast, colorectal, and other cancers in women with newly dia gnosed endometriosis or adenomyosis: a population-based study. Int J Gynecol Cancer 2015; 25 (6): 968–976. doi: 10.1097/IGC.0000000000000454.

5. Kumar S, Munkarah A, Arabi H et al. Prognostic analysis of ovarian cancer associated with endometriosis. Am J Obstet Gynecol 2011; 204 (1): 63.e1–63.e7. doi: 10.1016/j.ajog.2010.08.017.

6. Murta EF, Nomelini RS. Early dia gnosis and predictors of malignancy in the evaluation of adnexal mass. Curr Opin Obstet Gynecol 2006; 18 (1): 14–19. doi: 10.1097/01.gco.000019 2967.67567.e9.

7. Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet 2014; 290 (5): 839–842. doi: 10.1007/s00404-014-3364-8.

8. Jiang X, Hitchcock A, Bryan EJ et al. Micro satellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 1996; 56 (15): 3534–3539.

9. Li J, Liu R, Tang S et al. Impact of endometriosis on risk of ovarian, endometrial and cervical cancers: a meta-analysis. Arch Gynecol Obstet 2019; 299 (1): 35–46. doi: 10.1007/s00404-018-4968-1.

10. Králíčková M, Laganà AS, Ghezzi F et al. Endometriosis and risk of ovarian cancer: what do we know? Arch Gynecol Obstet 2020; 301 (1): 1–10. doi: 10.1007/s00404-019-05358-8.

11. Crispim PC, Jammal MP, Murta EF et al. Endometriosis: what is the influence of immune cells? Immunol Invest 2021; 50 (4): 372–388. doi: 10.1080/08820139.2020.1764577.

12. Zou G, Wang J, Xu X et al. Cell subtypes and immune dysfunction in peritoneal fluid of endometriosis revealed by single-cell RNA--sequencing. Cell Biosci 2021; 11 (1): 98. doi: 10.1186/s13578-021-00613-5.

13. Li WN, Hsiao KY, Wang CA et al. Extracellular vesicle-associated VEGF-C promotes lymphangiogenesis and immune cells infiltration in endometriosis. Proc Natl Acad Sci U S A 2020; 13; 117 (41): 25859–25868. doi: 10.1073/pnas.1920037117.

14. Kyama CM, Debrock S, Mwenda JM et al. Potential involvement of the immune system in the development of endometriosis. Reprod Biol Endocrinol 2003; 1: 123. doi: 10.1186/1477-7827-1-123.

15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144 (5): 646–674. doi: 10.1016/j.cell.2011.02.013.

16. Wang X, Wang E, Kavanagh JJ et al. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 2005; 3: 25. doi: 10.1186/1479-5876-3-25.

17. Restifo NP, Wunderlich JR. Molecular bio logy of cancer: cancer immunology. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins 2005: 139.

18. Plewka D, Kowalczyk AE, Jakubiec-Bartnik B et al. Immunohistochemical visualization of pro-inflammatory cytokines and enzymes in ovarian tumors. Folia Histochem Cytobio l 2014; 52 (2): 124–137. doi: 10.5603/FHC.2014.0015.

19. Qu H, Li L, Wang TL et al. Epithelial cells in endometriosis and adenomyosis upregulate STING expression. Reprod Sci 2020; 27 (6): 1276–1284. doi: 10.1007/s43032-019-00127-z.

20. Guo M, Bafligil C, Tapmeier T et al. Mass cytometry analysis reveals a distinct immune environment in peritoneal fluid in endometriosis: a characterisation study. BMC Med 2020; 18 (1): 3. doi: 10.1186/s12916-019-1470-y.

21. Wang XQ, Zhou WJ, Luo XZ et al. Synergistic effect of regulatory T cells and proinflammatory cytokines in angiogenesis in the endometriotic milieu. Hum Reprod 2017; 32 (6): 1304–1317. doi: 10.1093/humrep/dex067.

22. D’Hooghe TM, Debrock S, Hill JA et al. Endometriosis and subfertility: is the relationship resolved? Semin Reprod Med 2003; 21 (2): 243–254. doi: 10.1055/s-2003-41330.

23. Lebovic DI, Mueller MD, Taylor RN. Immunobio logy of endometriosis. Fertil Steril 2001; 75 (1): 1–10. doi: 10.1016/s0015-0282 (00) 01630-7.

24. Tamaresis JS, Irwin JC, Goldfien GA et al. Molecular classification of endometriosis and dis ease stage using high-dimensional genomic data. Endocrinology 2014; 155 (12): 4986–4999. doi: 10.1210/en.2014-1490.

25. Montgomery GW, Nyholt DR, Zhao ZZ et al. The search for genes contributing to endometriosis risk. Hum Reprod Update 2008; 14 (5): 447–457. doi: 10.1093/humupd/dmn016.

26. Govindan S, Ahmad SN, Vedicherla B et al. Association of progesterone receptor gene polymorphism (PROGINS) with endometriosis, uterine fibroids and breast cancer. Cancer Biomarkers 2007; 3 (2): 73–78. doi: 10.3233/cbm-2007-3201.

27. Babaabasi B, Ahani A, Sadeghi F et al. The association between TNF-alpha gene polymorphisms and endometriosis in an Iranian population. Int J Fert Steril 2019; 13 (1): 6–11. doi: 10.22074/ijfs.2019.5542.

28. Saliminejad K, Memariani T, Ardekani AM et al. Association study of the TNF-a -1031T/C and VEGF +450G/C polymorphisms with susceptibility to endometriosis. Gynecol Endocrinol 2013; 29 (11): 974–977. doi: 10.3109/09513590.2013.824956.

29. Keenan JA, Chen TT, Chadwell NL et al. IL-1 beta, TNF-alpha, and IL-2 in peritoneal fluid and macrophage-conditioned media of women with endometriosis. Am J Reprod Immunol 1995; 34 (6): 381–385. doi: 10.1111/j.1600-0897.1995.tb00968.x.

30. Braun DP, Gebel H, House R et al. Spontaneous and induced synthesis of cytokines by peripheral blood monocytes in patients with endometriosis. Fertil Steril 1996; 65 (6): 1125–1129.

31. Tsudo T, Harada T, Iwabe T et al. Altered gene expression and secretion of interleukin-6 in stromal cells derived from endometriotic tissues. Fertil Steril 2000; 73 (2): 205–211. doi: 10.1016/s0015-0282 (99) 00496-3.

32. Bergqvist A, Bruse C, Carlberg M et al. Interleukin 1beta, interleukin-6, and tumor necrosis factor-alpha in endometriotic tissue and in endometrium. Fertil Steril 2001; 75 (3): 489–495. doi: 10.1016/s0015-0282 (00) 01752-0.

33. Ulukus M, Ulukus EC, Seval Y et al. Expression of interleukin-8 receptors in endometriosis. Human Reprod 2005; 20 (3): 794–801. doi: 10.1093/humrep/deh675.

34. Ulukus M, Ulukus EC, Tavmergen Goker EN et al. Expression of interleukin-8 and monocyte chemotactic protein 1 in women with endometriosis. Fertil Steril 2009; 91 (3): 687–693. doi: 10.1016/j.fertnstert.2007.12.067.

35. Gatla HR, Singha B, Persaud V et al. Evaluating cytoplasmic and nuclear levels of inflammatory cytokines in cancer cells by western blotting. Methods Mol Biol 2014; 1172: 271–283. doi: 10.1007/978-1-4939-0928-5_25.

36. Llarena NC, Richards EG, Priyadarshini A et al. Characterizing the endometrial fluid cytokine profile in women with endometriosis. J Assist Reprod Genet 2020; 37 (12): 2999–3006. doi: 10.1007/s10815-020-01989-y.

37. Pizzo A, Salmeri FM, Ardita FV et al. Behaviour of cytokine levels in serum and peritoneal fluid of women with endometriosis. Gynecol Obstet Invest 2002; 54 (2): 82–87. doi: 10.1159/000067717.

38. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011; 23 (5): 598–604. doi: 10.1016/j.coi.2011.08.003.

39. Velasco I, Quereda F, Bermejo R et al. Intraperitoneal recombinant interleukin-2 activates leukocytes in rat endometriosis. J Reprod Immunol 2007; 74 (1–2): 124–132. doi: 10.1016/j.jri.2006.12.001.

40. Blumenthal RD, Samoszuk M, Taylor AP et al. Degranulating eosinophils in human endometriosis. Am J Pathol 2000; 156 (5): 1581–1588. doi: 10.1016/S0002-9440 (10) 65030-4.

41. Giampaolino P, Foreste V, Della Corte L et al. Role of bio markers for early detection of ovarian cancer recurrence. Gland Surg 2020; 9 (4): 1102–1111. doi: 10.21037/gs-20-544.

ORCID authors

R. Simões Nomelin 0000-0001-6591-7619

P. K. Aparecia Antão 0000-0002-4294-5892

M. Prata Jammal 0000-0003-2693-8817

C. Almeida de Lima 0000-0002-6926-558X

P. C. Arvelos Crispim 0000-0003-2637-2462

A. Martins-Filho 0000-0002-2519-5583

R. M. Etchebehere 0000-0002-2241-5966

E. F. Candido Murta 0000-0003-4014-1345

Submitted/Doručeno: 28. 4. 2024

Accepted/Přijato: 30. 4. 2024

Prof. Rosekeila Simões Nomelini, MD